老年评估引导干预措施加速 60 岁及以上 B 细胞非霍奇金淋巴瘤或多发性骨髓瘤患者 CAR-T 治疗后的功能恢复,GOCART 研究
老年 (G) 评估引导优化 (O) 以加速 60 岁及以上 B 细胞非霍奇金淋巴瘤或多发性骨髓瘤 (GOCART) 患者嵌合抗原受体 T 细胞 (CAR-T) 治疗后的功能恢复
This clinical trial compares the effectiveness of geriatric assessment (GA) guided interventions to accelerate functional recovery after chimeric antigen receptor T-cell (CAR-T) therapy compared to standard of care (SOC) in patients 60 years and older with B-cell non-Hodgkin lymphoma (NHL) or multiple myeloma (MM). A large number of patients diagnosed with cancer are over the age of 60, yet most cancer treatments are developed for younger patients. Therefore, older patients may be less likely to be offered stronger treatments, such as CAR-T therapy, due to possible side effects. Geriatric assessment is a multi-dimensional health assessment tool combining patient reported and objective measures covering physical function, mental processes (cognitive), and nutrition. Pre-treatment assessments may identify weaknesses in older adults and may guide interventions for physical therapy, cognitive changes and nutrition to decrease CAR-T therapy side effects and improve care in older adults with NHL or MM.
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVE:
I. Evaluate the effects of a GA-informed multi-disciplinary intervention in attenuating physical function decline among older patients receiving CAR-T therapy at day +30 post-CAR-T infusion.
SECONDARY OBJECTIVES:
I. Determine success in coordinating trimodality optimization before lymphodepletion.
II. Compare rates of geriatric syndromes of frailty, cognitive impairment and malnourishment in SOC and GA-intervention cohorts at 30 days post-CAR-T infusion.
III. Evaluate rates and duration of CAR-T related neurotoxicity in SOC and GA-intervention groups.
EXPLORATORY OBJECTIVES:
I. Quantify trimodality optimization intensity throughout treatment course. II. Compare longitudinal trajectory of Short Physical Performance Battery (SPPB), frailty, cognitive impairment and malnourishment between the two arms, at day +100 post-CAR-T infusion.
III. Evaluate quality of life trajectories using the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale at baseline and days +30 and +100 in both cohorts.
IV. Incidence of intensive care unit (ICU) admissions by day 100. V. Overall survival, response rate and progression-free survival through one year.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo GA before lymphodepleting chemotherapy and recommendations based on assessment results communicated to treating physicians. Patients receive physical therapy (PT) and delirium prevention education prior to lymphodepletion, at least once before CAR-T therapy, at least 2 times a week while inpatient, and at least once every other week outpatient up to day 30. Additionally, patients receive personalized nutritional guidance from a registered dietician prior to lymphodepletion, prior to CAR-T therapy and at least once a week up to day 30.
ARM II: Patients undergo GA and receive standard of care throughout study.
After completion of study treatment, patients are followed up at day 100 and then up to 1 year.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
California
-
Duarte、California、美国、91010
- 招聘中
- City of Hope Medical Center
-
接触:
- Andrew S. Artz
- 电话号码:626-218-2405
- 邮箱:aartz@coh.org
-
首席研究员:
- Andrew S. Artz
-
Irvine、California、美国、92618
- 招聘中
- City of Hope at Irvine Lennar
-
接触:
- Andrew Artz, MD
- 电话号码:626-218-2405
- 邮箱:aartz@coh.org
-
-
North Carolina
-
Winston-Salem、North Carolina、美国、27157
- 招聘中
- Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology
-
接触:
- Heidi Klepin, MD
- 电话号码:336-716-2255
- 邮箱:hklepin@wakehealth.edu
-
-
Ohio
-
Columbus、Ohio、美国、43210
- 招聘中
- Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology
-
接触:
- Ashley Rosko, MD
- 电话号码:614-293-7807
- 邮箱:ashley.rosko@osumc.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Ability to provide informed consent
- Patient's physician must agree for patient participation. A physician may elect to provide blanket agreement for participation of any eligible CAR-T patient under their care
- Ability to read English, or Spanish. Other languages will be acceptable with site principal investigator (PI) agreement if surveys are available and language does not preclude completing study procedures
- Age: >= 60 years at the time of enrollment
- Scheduled to receive an Food and Drug Administration (FDA)-approved CAR-T for treatment of multiple myeloma or B-cell non- Hodgkin lymphoma
- Willing and able to complete study requirements
- Patients expect to be able to participate at least once before lymphodepletion with trimodality optimization visits
Exclusion Criteria:
- Prior CAR-T therapy
- Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm I (PT, cognitive education, nutrition education)
Patients undergo GA before lymphodepleting chemotherapy and recommendations based on assessment results communicated to treating physicians. Patients receive PT and delirium prevention education prior to lymphodepletion, at least once before CAR-T therapy, at least 2 times a week while inpatient, and at least once every other week outpatient up to day 30. Additionally, patients receive personalized nutritional guidance from a registered dietician prior to lymphodepletion, prior to CAR-T therapy and at least once a week up to day 30. |
Ancillary studies Receive delirium prevention education Undergo geriatric assessment Undergo nutritional optimization Undergo physical function optimization
其他名称:
|
|
有源比较器:Arm II (standard of care)
Patients undergo GA and receive standard of care throughout study. |
Ancillary studies Undergo standard of care
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Changes in Short Physical Performance Battery (SPPB)
大体时间:From baseline to day 30 after chimeric antigen receptor T-cell (CAR-T) infusion
|
T-test will be used to compare SPPB changes score between two arms at 30 days after CAR-T infusion. |
From baseline to day 30 after chimeric antigen receptor T-cell (CAR-T) infusion
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Successful in coordinating initial optimization
大体时间:From enrollment to start of lymphodepletion
|
A physical or virtual visit will be tabulated separately for functional optimization, delirium prevention and nutrition. Adherence will be deemed to have been met if >=70% or more comlete tri-modality optimization before lymphodepletion in the modified intent to treat population. |
From enrollment to start of lymphodepletion
|
|
Frailty progression
大体时间:At 30 days post CAR-T infusion
|
Frailty progression will be defined as a score of 3 or more at T2 if T1 not frail (<3); if frail at T1 (score 3-5), any worsening of the score; a score of 5 at day 30 if baseline score already at the maximum frailty of 5. |
At 30 days post CAR-T infusion
|
|
Cognitive impairment
大体时间:At 30 days post CAR-T infusion
|
Assessed using the Montreal Cognitive Assessment (MoCA). Cognitive impairment defined as MoCA score of < 23 or unable to complete the MoCA due to cognitive impairment. The proportion of patients with cognitive impairment at day 30, irrespective of baseline cognition, will be compared between the two arms using Chi-square test. |
At 30 days post CAR-T infusion
|
|
Weight loss
大体时间:Up to 30 days post CAR-T infusion
|
Malnourishment will be measured using weight loss and dichotomized as > 5% weight loss from baseline to day +30. The proportion of patients with over 5% weight loss from T1 to T2 will be compared between the two arms using Chi-square test. |
Up to 30 days post CAR-T infusion
|
|
CAR-T associated neurotoxicity
大体时间:Up to day 100
|
Assessed using American Society for Transplantation and Cellular Therapy consensus grading for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS). The time to neurotoxicity (days), the maximum grade (1-4) and the duration of neurotoxicity (days) will be recorded. The cumulative incidence of ICANS (percentages) will be compared between arms as well as the maximum grade (1-4), and duration of neurotoxicity (days). |
Up to day 100
|
合作者和调查者
调查人员
- 首席研究员:Andrew S Artz、City of Hope Medical Center
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 22422
- P30CA033572 (美国 NIH 拨款/合同)
- 22422 (其他标识符:City of Hope Medical Center)
- NCI-2023-04359 (注册表标识符:CTRP (Clinical Trial Reporting Program))
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.